Takahiro Masuda1,2, Fuminari Misawa1,3, Masayuki Takase1,4, John M Kane1,5,6, Christoph U Correll1,5,6,7. 1. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York. 2. Sumitomo Dainippon Pharma Co, Ltd, Medical Affairs, Tokyo, Japan. 3. Yamanashi Prefectural KITA Hospital, Yamanashi, Japan. 4. Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan. 5. Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York. 6. Feinstein Institute for Medical Research, Manhasset, New York. 7. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
Abstract
Importance: Recent meta-analyses of randomized clinical trials (RCTs) comparing clozapine with nonclozapine second-generation antipsychotics (NC-SGAs) in schizophrenia have challenged clozapine's superiority in treatment-resistant patients. However, patients in RCTs are not necessarily generalizable to those in clinical practice. Objective: To conduct a systematic review and meta-analysis to compare various outcomes of clozapine vs oral NC-SGAs in cohort studies. Data Sources: Systematic literature search in PubMed, PsycINFO, and CINAHL without language restriction from database inception until December 17, 2018. Study Selection: Nonrandomized cohort studies reporting effectiveness and/or safety outcomes comparing clozapine with NC-SGAs in schizophrenia or schizoaffective disorder. Data Extraction and Synthesis: Independent investigators assessed studies and extracted data. Using a random-effects model, the study calculated risk ratio (RR) unadjusted for covariates and follow-up duration, number needed to treat/number needed to harm (NNT/NNH) for dichotomous data, and standardized mean difference (SMD) or mean difference (MD) for continuous data. Main Outcomes and Measures: Coprimary outcomes were hospitalization and all-cause discontinuation. Secondary outcomes included all effectiveness and safety outcomes reported in at least 3 analyzable studies. Results: Of 8446 hits, 68 articles from 63 individual cohort studies (n = 109 341) (60.3% male; mean [SD] age of 38.8 [6.5] years, illness duration of 11.0 [5.1] years, and study duration of 19.1 [23.3] months) were meta-analyzed. Compared with NC-SGAs, despite greater illness severity (17 studies [n = 38 766]; Hedges g, 0.222; 95% CI, 0.013-0.430; P = .04), clozapine was significantly associated with lower hospitalization risk (19 studies [n = 49 453]; RR, 0.817; 95% CI, 0.725-0.920; P = .001; NNT, 18; 95% CI, 12-40) and all-cause discontinuation (16 studies [n = 56 368]; RR, 0.732; 95% CI, 0.639-0.838; P < .001; NNT, 8; 95% CI, 6-12). Associations were statistically significant for comparisons with quetiapine fumarate and aripiprazole regarding hospitalization and all NC-SGAs, except aripiprazole, for all-cause discontinuation. Clozapine was also significantly associated with better outcomes regarding overall symptoms (SMD, -0.302; 95% CI, -0.572 to -0.032; P = .03) and Clinical Global Impressions scale severity (SMD, -1.182; 95% CI, -2.243 to -0.122; P = .03). Clozapine was significantly associated with increases in body weight (MD, 1.70; 95% CI, 0.31-3.08 kg; P = .02), body mass index (MD, 0.96; 95% CI, 0.24-1.68; P = .009), and type 2 diabetes (RR, 1.777; 95% CI, 1.229-2.570; P = .002; NNH, 27; 95% CI, 13-90). Conclusions and Relevance: In cohort studies, despite more severely ill patients being treated with clozapine, use of clozapine was associated with better key efficacy outcomes and higher cardiometabolic-related risk outcomes vs NC-SGAs.
Importance: Recent meta-analyses of randomized clinical trials (RCTs) comparing clozapine with nonclozapine second-generation antipsychotics (NC-SGAs) in schizophrenia have challenged clozapine's superiority in treatment-resistant patients. However, patients in RCTs are not necessarily generalizable to those in clinical practice. Objective: To conduct a systematic review and meta-analysis to compare various outcomes of clozapine vs oral NC-SGAs in cohort studies. Data Sources: Systematic literature search in PubMed, PsycINFO, and CINAHL without language restriction from database inception until December 17, 2018. Study Selection: Nonrandomized cohort studies reporting effectiveness and/or safety outcomes comparing clozapine with NC-SGAs in schizophrenia or schizoaffective disorder. Data Extraction and Synthesis: Independent investigators assessed studies and extracted data. Using a random-effects model, the study calculated risk ratio (RR) unadjusted for covariates and follow-up duration, number needed to treat/number needed to harm (NNT/NNH) for dichotomous data, and standardized mean difference (SMD) or mean difference (MD) for continuous data. Main Outcomes and Measures: Coprimary outcomes were hospitalization and all-cause discontinuation. Secondary outcomes included all effectiveness and safety outcomes reported in at least 3 analyzable studies. Results: Of 8446 hits, 68 articles from 63 individual cohort studies (n = 109 341) (60.3% male; mean [SD] age of 38.8 [6.5] years, illness duration of 11.0 [5.1] years, and study duration of 19.1 [23.3] months) were meta-analyzed. Compared with NC-SGAs, despite greater illness severity (17 studies [n = 38 766]; Hedges g, 0.222; 95% CI, 0.013-0.430; P = .04), clozapine was significantly associated with lower hospitalization risk (19 studies [n = 49 453]; RR, 0.817; 95% CI, 0.725-0.920; P = .001; NNT, 18; 95% CI, 12-40) and all-cause discontinuation (16 studies [n = 56 368]; RR, 0.732; 95% CI, 0.639-0.838; P < .001; NNT, 8; 95% CI, 6-12). Associations were statistically significant for comparisons with quetiapine fumarate and aripiprazole regarding hospitalization and all NC-SGAs, except aripiprazole, for all-cause discontinuation. Clozapine was also significantly associated with better outcomes regarding overall symptoms (SMD, -0.302; 95% CI, -0.572 to -0.032; P = .03) and Clinical Global Impressions scale severity (SMD, -1.182; 95% CI, -2.243 to -0.122; P = .03). Clozapine was significantly associated with increases in body weight (MD, 1.70; 95% CI, 0.31-3.08 kg; P = .02), body mass index (MD, 0.96; 95% CI, 0.24-1.68; P = .009), and type 2 diabetes (RR, 1.777; 95% CI, 1.229-2.570; P = .002; NNH, 27; 95% CI, 13-90). Conclusions and Relevance: In cohort studies, despite more severely ill patients being treated with clozapine, use of clozapine was associated with better key efficacy outcomes and higher cardiometabolic-related risk outcomes vs NC-SGAs.
Authors: Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll Journal: Nat Rev Endocrinol Date: 2011-10-18 Impact factor: 43.330
Authors: A Vanasse; L Blais; J Courteau; A A Cohen; P Roberge; A Larouche; S Grignon; M-J Fleury; A Lesage; M-F Demers; M-A Roy; J-D Carrier; A Delorme Journal: Acta Psychiatr Scand Date: 2016-07-12 Impact factor: 6.392
Authors: Gunilla Ringbäck Weitoft; Mats Berglund; Eva A Lindström; Mikael Nilsson; Peter Salmi; Måns Rosén Journal: Pharmacoepidemiol Drug Saf Date: 2014-01-17 Impact factor: 2.890
Authors: Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind Journal: Psychopharmacology (Berl) Date: 2021-01-07 Impact factor: 4.530
Authors: Graham Blackman; Ebenezer Oloyede; Mark Horowitz; Robert Harland; David Taylor; James MacCabe; Philip McGuire Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 9.306
Authors: Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas Journal: Psychother Psychosom Date: 2020-04-14 Impact factor: 17.659